For healthcare professionals. Compounded preparations are dispensed on a doctor’s prescription.
Short answer: A 2013 placebo-controlled trial in knee osteoarthritis found that chondroitin 4&6 sulfate improved symptoms more than placebo over three months (Osteoarthritis and Cartilage, 2013; PMID 23059756). A 2025 pilot of a multi-ingredient formulation did not achieve its primary endpoint (Scientific Reports, 2025; PMID 40664872). Any compounded preparation is made for one named patient, on a doctor’s prescription.
Why a chondroitin request is written in parts
A chondroitin sulphate request names more than the active. The strength per unit, the dosage form the patient can take and the excipient profile each change what the patient actually receives, and a registered product may not match all three. The prescriber sets each part. The pharmacy prepares the specification as written and does not infer the strength or the form from the name of the active.
Who the trials enrolled
The 2013 trial enrolled adults over 45 with knee osteoarthritis whose symptoms met its minimum thresholds: a Lequesne index of 7 or more and pain of at least 40 mm on a visual analogue scale (Osteoarthritis and Cartilage, 2013; PMID 23059756). The 2025 pilot enrolled adults with mild to moderate knee pain (Scientific Reports, 2025; PMID 40664872). The two populations differ in severity, so a reader should not pool their results into a single estimate.
What the 2013 trial tested and found
The 2013 study is the main single-active trial cited in this article. It was a comparative, double-blind, randomised, multicentre trial of 353 people over 45 years of age with knee osteoarthritis. Participants received a single daily oral 1200 mg sachet of chondroitin 4&6 sulfate, three daily 400 mg capsules of the same active, or placebo, for three months (Osteoarthritis and Cartilage, 2013; PMID 23059756).
After three months, the abstract reports no significant difference between the single daily sachet and the three-capsule regimen. Both chondroitin groups were significantly improved compared with placebo on the Lequesne index and on VAS pain. No significant difference in security and tolerability was seen between the three groups (Osteoarthritis and Cartilage, 2013; PMID 23059756).
What the 2025 pilot tested and found
The 2025 pilot (Scientific Reports, 2025; PMID 40664872) did not test chondroitin alone. Its formulation combined collagen type II, glucosamine hydrochloride and chondroitin sulfate. Fifty-four adults were enrolled over 12 weeks, and 52 completed the study.
The abstract reports improvements in several Knee injury and Osteoarthritis Outcome Score (KOOS) subscales, in stiffness and in quality of life in the verum (active) group compared with placebo. It also states that the study did not achieve its primary endpoint, and that the authors consider larger confirmatory trials warranted (Scientific Reports, 2025; PMID 40664872).
Reading the two studies together
The two studies answer different questions. The 2013 trial asked whether chondroitin 4&6 sulfate given alone outperformed placebo in knee osteoarthritis. The 2025 pilot asked whether a combined product helped, and it did not meet its primary endpoint. Neither result can be carried over to the other. The abstracts do not describe a compounded preparation, so neither result transfers automatically to a formulation prepared in Malaysia.
The outcome measures a prescriber should recognise
The Lequesne index is a questionnaire-based score of knee or hip osteoarthritis symptoms and function. VAS pain is a line on which the patient marks pain intensity. KOOS covers pain, symptoms, function, sport and recreation, and quality of life. A change on one scale does not show the same change on another, so a prescriber reading a trial result should check which measure produced it.
Summary of the two studies
| Study | Population | Product or regimen tested | Result as reported | PMID |
|---|---|---|---|---|
| Osteoarthritis and Cartilage, 2013 | 353 adults over 45 with knee osteoarthritis | Chondroitin 4&6 sulfate: 1200 mg once daily as a sachet, or 400 mg three times daily as capsules; placebo | Both chondroitin regimens significantly better than placebo on Lequesne index and VAS pain at three months; no significant difference between regimens | 23059756 |
| Scientific Reports, 2025 | 54 enrolled, 52 completed; mild to moderate knee pain; 12 weeks | Collagen type II, glucosamine hydrochloride and chondroitin sulfate combined; placebo | Several KOOS subscale and stiffness improvements in the active group; primary endpoint not achieved | 40664872 |
Strength, grade and excipients
Strength is the prescriber’s decision and is written per unit. The 2013 abstract names chondroitin 4&6 sulfate, so a request for a different salt or grade is not the product that trial tested, and the prescriber should say so on the request. Any excipient the patient must avoid is named in full, so the exclusion is visible before preparation begins.
Forms and what the prescriber states for each
Chondroitin is requested as a non-sterile capsule or as a powder in a container. For a capsule, the prescriber states the chondroitin 4&6 sulfate content in each capsule, the grade where it matters, and the number of capsules to be made. For a powder, the prescriber states the amount per measured dose, the container and the total quantity, and the once-daily or three-times-daily pattern intended. Liposomal or ordinary delivery is a separate choice, recorded with its reason.
Copying a trial regimen onto a request
The 2013 trial used two regimens: one 1200 mg daily sachet, and three 400 mg capsules daily. A prescriber who wants to mirror either regimen writes the strength and the frequency on the request. A compounded preparation is not the product that was tested, so the regimen is a reference point, not a promise of the same result in the named patient.
Before writing the request
- Confirm the diagnosis and the joint involved; both trials concern knee osteoarthritis only.
- Decide whether the 2013 regimen, a different strength or a different form is required, and write the choice down.
- State the strength per unit, the form, the quantity and the directions for use.
- Name any excipient the patient must avoid and any documented reaction.
- Record the reason a registered product does not fit.
Reasons a registered chondroitin product may not fit
The reason a compounded chondroitin request is made belongs on the prescription. Common examples are a strength that a registered product does not supply, a dosage form the patient cannot take, or an excipient the patient must avoid. The prescriber states the reason in clinical terms. The pharmacy does not choose it for the patient.
Evidence limits
- Both trials concern knee osteoarthritis only, and their findings do not extend to hip, hand or spinal disease.
- The 2013 trial assessed symptoms at baseline and after one to three months, and the abstract reports its result at three months.
- The 2025 pilot was small, with 52 completers, and did not meet its primary endpoint.
- The abstracts do not describe a compounded preparation.
Related reading
The closest related specification in this series is the Boswellia article on compounded Boswellia (AKBA) in Malaysia for joint clinics, which covers a different active in the same clinic setting. Chondroitin preparations are made to the Good Compounding Practice (GCP) standard; the laboratory page is where that standard is documented.
How to prescribe
Only a registered doctor writes a chondroitin sulphate request, and it is made for one named patient. It states the active (chondroitin sulphate, with the salt or grade where it matters), the strength per unit, the form (a capsule or a powder in a container), the quantity, the directions for use, the patient’s name, and the prescriber’s name, signature and date.
Once signed, the request is sent to Lynnity via the contact page, after the prescriber has checked the referral items in the prescriber’s checklist for referrals, prescriptions and GCP compliance.
Specification review: Vitthia Rama Murti, RPh (RPh 15632).
Frequently asked questions
What did the 2013 trial find for chondroitin sulphate in knee osteoarthritis?
In 353 adults with knee osteoarthritis, chondroitin 4&6 sulfate given as a single daily 1200 mg sachet or as three daily 400 mg capsules improved significantly more than placebo over three months on the Lequesne index and VAS pain (Osteoarthritis and Cartilage, 2013; PMID 23059756). The two chondroitin regimens did not differ significantly from each other.
Did the 2025 pilot show that chondroitin works?
The 2025 pilot tested a formulation of collagen type II, glucosamine hydrochloride and chondroitin sulfate, not chondroitin alone. It did not achieve its primary endpoint, although several patient-reported measures favoured the active group (Scientific Reports, 2025; PMID 40664872).
Should a prescriber specify a capsule or a powder?
That is the prescriber’s decision. A capsule is specified by the content per capsule and the number to be made. A powder in a container is specified by the amount per measured dose, the container and the total quantity. Any excipient to avoid is named on the request.